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To diagnose an HCV infection is expensive because it is important to know to what extent seropositive patient 
is or not, viremic. The study aimed to define the best combination of serological tools to use in order to get the 
best prediction for HCV viremia at cheaper cost. The study questions focused on: usefulness of repeat tests, 
relevance of EIA test ratio (TR) values, use of a confirmatory test or a second screening test, costs of these 
alternatives, and choosing the best option giving an excellent probability of HCV-RNA detection. Costs were 
calculated using estimates for each EIA test, LIA-HCV, and PCR. Global data from two epidemiological surveys 
carried out between 2009-2010 in Mali were used. By using as an indicator, the magnitude of the signal-to-cutoff 
ratio measured with EIA, PPV (Positive Predictive value) of the presence of HCV RNA significantly increased 
from 41.2% to 82.4%. The highest PPV was obtained by performing two 4
th
 generation EIA tests and exploitation 
of the threshold (half of the maximal ratio value measured). The cost of additional tests for virus detection 
ranged between 3550 USD and 1155 USD, and the algorithm presenting the highest PPV (87.5%) was not the 
most expensive (1551 USD). 
 




Viral hepatitis is a result of liver inflammation caused by a 
virus, and there are five dominant hepatotropic viruses 
whose hepatitis C virus (HCV) (Trepo, 2006). Height HCV 
genotypes with 86 subtypes exist (Borgia, 2018; 
Hedskog, 2019) plus a subtype 6xg newly discovered 
from injection drug users (IDUs) (Ye, 2019).  
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Although both genotypes one and two are reported in 
Mali, genotype 2 is predominant (easier to treat than 
genotype 1) (Bouare, 2012). Due to the disease 
prevalence, chronicity and related possible complications, 
viral hepatitis C is a significant public health concern 
worldwide. It is a high-risk viral hepatitis type because it can 
develop into a chronic disease with complicated outcomes 
such as liver cirrhosis and hepatocellular carcinoma (HCC). 
Globally it is reported that 71 million people have chronic 








them (mostly from cirrhosis and hepatocellular 
carcinoma) (WHO, 2018). The geographical distribution is 
variable with high prevalence regions such as Africa and 
Asia, where the prevalence exceeds 10%. In West Africa, 
WHO reported an HCV seroprevalence rate of 5.3% 
[95% CI: 2.9-9.1%] (WHO, 2016). Although, seemingly 
fewer cases in Mali, HCV epidemiological reports from 
recent literature, show both a prevalence and nosocomial 
transmission risk of hepatitis C virus infection (Bouare, 
2013). We previously reported HCV prevalences of 0.2% 
and 6.5% respectively among pregnant women from six 
health centers and women aged over 50 years attending 
general practice in two hospitals in Bamako (Bouare, 
2012). HCV seroprevalence rate of 10% was reported 
among diabetic patients from two health care facilities in 
Bamako (Diarra, 2013). In the absence of a vaccine, 
hygiene and safety precautions in hospitals and health 
centers, blood safety measures, systematic screening, 
treatment, treatment adherence, and its accessibility 
contribute to HCV infection eradication measures. Direct 
diagnosis of HCV by polymerase chain reaction (PCR) is 
expensive and requires considerable resources. The big 
question related to serology of hepatitis C is the 
identification of the extent to which a seropositive patient 
is viremic. Significant improvement in the 
positive/negative predictive value for the indirect 
diagnosis of viremia can be achieved by combining 
different serological tests, including HCV antibody (anti-
HCV IgM) (Gerard, 1996). Furthermore, studies 
addressing HCV diagnostic accuracy were reported, but 
such investigations are relatively scarce in Mali. A high 
degree of accuracy between HCV viremia and test ratio 
value (TR, signal-to-cutoff ratio) was reported for the anti-
HCV test (Seo, 2009; Cao, 2011; Bouare, 2012). We 
previously showed a 66.7% viremia prediction for 
samples with TR higher than 50% of the maximal signal 
value measured with an antibody test (anti-HCV) 
(Bouare, 2012). Therefore, undoubtedly this is an 
important study to generate new knowledge in the field of 
HCV diagnosis and therapeutic management in Mali, thus 
stimulating scientific interest to investigate the best 
predictive methods for evaluation of HCV-RNA presence 
at a cheaper cost.  
 
 




Two investigations were undertaken in Mali, successively 
in 2009 in pregnant women recruited from the six reference  
health centers in Bamako and in 2010, among women 
over 50 years old who frequented the general practice in 
two hospitals (CHU Gabriel Touré, and Hospital Mother 
and Child) from the same city (Bouare, 2012; Bouaré, 
2013).  
Initially, this was a cross-sectional study including 1000 
pregnant women attending antenatal care (ANC). 
In a second step, the study was extended to women over 
50 years, for the higher risk of HCV infection in that age. 
In fact, 231 women > 50 years were enrolled. 
Standard operating procedures were issued to control 
blood collection, preservation and transport. Physicians, 
researchers, midwives and laboratory technicians were 
trained in the application of procedures. Sample transport 
by drivers was supervised. The venous blood collected in 
vacutainer tubes. Serum or plasma were prepared, 
aliquoted, and stored frozen between -20 and -80°C 
before being transferred in good condition to Liege 
University Hospital for analysis. This work was conducted 
by following the guidelines of the World Medical 
Association Declaration of Helsinki (2000) and ethically 
approved under reference number 08-0006 / INRSP-EC 
(Ethical Committee of National Institute of Research in 
Public Health) in Mali. All women enrolled were 
randomized after a written informed and voluntary (opt 





The laboratory tests were performed according to the 
manufacturer's instructions (used for testing) and 
according to the accredited procedures (standard 
EN15189) applied to the AIDS reference laboratory of the 
CHU of Liege. The samples were analyzed after a single 
thaw. 
Serology: The mixed test MONOLISA HCV Ab/Ag Ultra 
4
th
 Generation (Bio-Rad Belgium) was used in both sets 
of women (young and old), while the antibody test 
(INNOTEST HCV Ab IV 4
th
 Generation) (Innogenetics 
Belgium, currently called Fujirebio Europe) was used only 
in the young set. The antibody test (INNOTEST) was 
regarded as a second screening test. Both tests are 
based on the enzyme-linked immunosorbent assay 
(ELISA) principle. While MONOLISA performs dual 
detection of Ag HCV and Ab (anti-HCV IgG), INNOTEST 
detects Ab alone (anti-HCV IgG). The confirmatory test 
INNO-line immuno-assay (LIA) HCV, HCV score III v2 
(incubation 16 hours), using a LiRAS scanner (Line Reader 










Molecular biology: Samples tested positive or 
indeterminate with the LIA confirmation test were analyzed 
by PCR (qualitative or quantitative). For the first part of the 
study, the molecular biology test (COBAS AMPLICOR 
hepatitis C. Roche Laboratory) was used for HCV-RNA 
detection. Samples with detectable HCV-RNA were 
analyzed by quantitative PCR (COBAS AMPLICOR HCV 
Monitor, Roche Laboratory). For the second part of the study 
conducted among older women, HCV m2000 real-time PCR 
kit (Abbott), was used to quantify HCV-RNA. All samples 
tested positive by the mixed test Monolisa but negative by 
the LIA, a priori indicative of very early infection, were re-
analyzed by PCR to check the status of HCV active 
infection. 
 
Search for the best algorithm 
 
To test patients for HCV with better diagnostic efficacy, 
we tried to develop algorithms that enhance infectious 
disease management of HCV in scarce resources areas 
like Mali, based on the global epidemiological data from 
thesis works and our observations and experience of the 
tests (Bouare, 2012; Bouaré, 2013). We attempted to 
answer questions to identify methods that give the best 
positive predictive value for HCV-RNA detection. Our 
questions focused on the usefulness of repeat tests, 
relevance of test ratio values, use of a confirmatory test 
or a second screening EIA test, costs of methods, and 
choosing the best option with an excellent probability of 
HCV-RNA detection at a cheaper cost. The serology was 
even used to implement the estimated threshold 50% 
TRmax, and its analytical implications. Data generated 
using indirect HCV diagnosis methods from two 
epidemiological surveys were analyzed for viremia 
prediction.  
The cost of additional tests was estimated for each 
diagnostic method implemented. For instance, when one 
considers an algorithm (Xi): Enzyme immunoassay (EIA) 
initial test positive + PCR; supplementary test to be done 
is equal to 0 for EIA + Nb PCR (i.e., the theoretical 
number of PCRs to run); Hence supplementary test cost 
= Nb PCR x (cost for one PCR test). Cost calculations 
are based on roughly estimates such as one EIA test 11 
USD, LIA-HCV 27.5 USD, and PCR 55 USD. We derive 
supplementary test cost for (Xi) = 55 USD x Nb PCR. The 
choice of a suitable alternative depends on the probability 




The results are presented as mean +/- standard deviation 
(SD) (range) or as median and quartiles for continuous 
variables, and frequencies (%) for categorical variables. 
The chi-square test was used to compare categorical 
variables between groups. PPV or probability of HCV-
RNA detection was calculated for each algorithm or 
diagnosis method. We tested whether TR value allows for 
a qualitative characterization of samples i.e. answering 
the question of presence or absence of specific anti-HCV 
antibodies, its value can be also exploited quantitatively. 
TR values were compared between PCR results (+ or -) 
by the Kruskal-Wallis test. Results were considered 
significant at the 5% level (p < 0.05). The calculations 
were by using the Microsoft Excel software and SAS 





For the first series of the study conducted in young 
pregnant women aged 14-50 years, mean age was 25.2 
± 6.3 years. As for the second series represented by 
women aged over 50 years, the average age was 62.1 ± 
8.6 years (range 51-89 years).  
 
HCV viremia prediction analysis 
 
The results from the diagnostic methods implemented are 
summarized below. 
Repeat the initial positive test: Out of the 50 positive or 
doubtful samples, 34 were re-analyzed by PCR, and 14 
were positive and 20 negatives (PPV = 41.2%). Among 
the 35 positive results from samples re-analyzed three 
times, 34 were tested by PCR, and PPV remained the 
same.  
The exploitation of TR values and 50% TRmax 
contribution: each test corresponds to a maximum value 
of the signal-to-cutoff Ratio (Test Ratio max or TRmax), 
which is the highest value of the signal measured in the 
positive samples. We tested that TR value can be 
exploited quantitatively. Indeed, we showed that the 
threshold 50% TRmax presents an interesting PPV as far 
as the presence of the virus itself is concerned. In other 
words, 50% of TRmax was able, with an interesting PPV, 
to discriminate between viremic and non-viremic patients. 
The following analysis focuses only on Monolisa test 
results since it was applied to both sets studied. 
Analyzing the sample data distribution (TR values 
according to PCR results) we demonstrated that TR 
values are higher for positive PCR than negative PCR 
(Median 5.66 Quartiles 5.42 – 5.91 vs. Median 1.90 
Quartiles 1.42 – 2.77; p<0.0001 P value from Kruskal-
















according to PCR results. In this study, the average values 
of TR (TR mean) were calculated from triplicate positive 
samples. TRmax (maximum signal value) was estimated as 
the maximum value of TR mean (TR mean max = TRmax = 
6), and the half value (50%TRmax = 3) measured from 
the Monolisa test. In the hypothesis where the samples 
with TR ≥ 3 are tested in replicates, PPV reached 82.4% 
in the samples whose TR remains three times ≥ 3. 
Regarding the initial test (Table 1), four samples with 
initial TR > 3 tested in replicates do not reproduce the TR 
three times ≥ 3 so that the number of samples to be 
analyzed by PCR drops from 21 to 17, thereby increasing 
the PPV significantly (41.2% (14/34) vs. 82.4% (14/17); 
p<0.01).  
Contribution of the confirmatory test INNO-LIA: In this 
alternative, the samples tested positive with the 
screening test were analyzed with the LIA confirmatory 
test. The PPV of the samples with LIA positive profiles 
was 81.2% (13/16). The PPV for indeterminate LIA 
profiles was 6.3% (1/16). Table 1 (see the alternative 
numbers 5, 7, and 8) shows, according to TR values, a 
regression of the LIA “indeterminate” rates. Indeed a high 
indeterminate rate 35% was obtained when the samples 
with TR ≥1 were tested with the LIA; a rate of 28.5% 
when samples with TR > 3 were tested; it drops down to 
17.6% when the samples with TR three times higher or 
equal to 50% TRmax were tested. In the hypothesis 
where samples with TR three times >3 were tested by the 
LIA (Table 1 alternative 8), PPV for the PCR was equal to 
82.4%. 
The usefulness of a second screening test: In this 
alternative, we evaluated the contribution of an additional 
EIA test used as a second-line assay rather than the LIA. 
In this case, for the first test, EIA1 TR = TR1 and the 
second test EIA2 TR = TR2. The method to get higher 




















Single screening EIA (Monolisa) N pos 
 
pos neg nt PCR pos neg Ind nt LIA 
1 TR ≥ 0.9 (±10%) tested 1x 50 0 0 50 41.2 14 20 16 34 0 0 0 0 0 
2 TR ≥ 1 tested 3x 35 100 0 35 41.2 14 20 1 34 0 0 0 0 0 
3 TR > 3 tested 1x 21 0 0 21 66.7 14 7 0 21 0 0 0 0 0 
4 TR > 3 tested 3x 17 42 0 17 82.4 14 3 0 17 0 0 0 0 0 
Monolisa + LIA 
 
5 TR ≥ 1 (±10%) tested 1x 44 0 44 29 41.2 14 20 10 34 15 9 14 6 29 
6 TR ≥ 1 tested 3x 35 100 35 27 41.2 14 20 1 34 15 8 12 0 27 
7 TR > 3 tested 1x 21 0 21 20 70.0 14 6 0 20 14 1 6 0 20 
8 TR > 3 tested 3x 17 42 17 17 82.4 14 0 0 14 14 1 3 0 17 
EIA1 (Monolisa) + EIA2 (Innotest) 
 
9 
TR ≥ 0.9 tested 1x  
(for the 2 tests) 
31 50 31 25 58.3 14 10 7 24 15 5 10 1 25 
10 
TR1 ≥ 3 for EIA1 1x and  EIA2 1x: 
selection of results with TR2 ≥ 3  




Perform a first test (EIA1); select samples with TR1 greater or equal to the 
threshold value 3 (i.e. 50% TRmax); test once (1x) with a second test (EIA2) and 
select samples whose TR2 is equally greater than or equal to 50% TR2max. In 
this study, TR2max was estimated equal to 6 with a threshold value of 3). Under 
these conditions, the PPV of this test combination reached 87.5% (14/16).  
 
Algorithm cost estimation 
 
HCV diagnostic accuracy with the economy of means is observed in three of the 
ten implemented alternatives (or algorithm) (Table 1 and 2). The corresponding 
number for these efficient alternatives is # 3, 4, and 10, which show viremia 
probabilities ranging between 66.7 and 87.5% for total testing costs between 
1155-1551 USD.   
 
Algorithm proposed for HCV Diagnosis 
 
The proposed algorithm (Figure 2) comprises a first line screening EIA (4
th
 
generation, ELISA principle); selection of the samples (with TR1 ≥ 50% TR1max) 
for analysis using a second screening EIA (4
th
 generation, ELISA principle). Under 
these conditions, for the samples whose TR2 ≥ TR2max 50%, the probability of 











As for the main findings, the present study demonstrates no change in the PPV of 
the EIA (Monolisa) with the test repeat. However, it is interesting to note that test 
repeat reduces the number of PCR runs and increases the PPV, used as an 
indicator for the magnitude of the signal-to-cutoff ratio measured from a single 
screening test coupled to the test repeat. The rate of decrease in LIA 
indeterminate profiles did not change the PPV, and the EIA test combination 
reached the highest PPV indicating that a patient with this profile has a probability 
of more than 85% to be actively infected with HCV (EASL conference abstract) 
(Bouare, 2013). The remaining samples (20%) can be considered anti-HCV 
positive but not HCV viremic; it can be either old infections or cured (most likely) 
or false positives for HCV (unlikely). This test combination is cost-effective with 
the highest probability for HCV-RNA detection with a corresponding 
supplementary test cost of 1551 USD. Our findings address two major concerns 
related to HCV infection diagnosis wherein we implemented an accurate cost-
saving method, based on both uses of two EIA-4 tests and considering the 
threshold 50% TRmax. This algorithm can be used for screening of infected 
patients likely to be treated and for HCV diagnosis in Mali, where a well-
documented cost-effective screening program is lacking. 










Cost estimation of algorithm 
(considering: EIA 11 USD; LIA 27.5 USD; PCR 55 USD). 
Single screening EIA (Monolisa) N pos 
 
EIA LIA PCR Total USD 
1 TR ≥ 0.9 (±10%) tested 1x 50 0 0 50 41.2 0 0 2750 2750 
2 TR ≥ 1 tested 3x 35 100 0 35 41.2 1100 0 1925 3025 
3 TR > 3 tested 1x 21 0 0 21 66.7 0 0 1155 1155 
4 TR > 3 tested 3x 17 42 0 17 82.4 462 0 935 1397 
Monolisa + LIA  
5 TR ≥ 1 (±10%) tested 1x 44 0 44 29 41.2 0 1210 1595 2805 
6 TR ≥ 1 tested 3x 35 100 35 27 41.2 1100 963 1485 3550 
7 TR > 3 tested 1x 21 0 21 20 70.0 0 578 1100 1678 
8 TR > 3 tested 3x 17 42 17 17 82.4 462 468 935 1865 
EIA1 (Monolisa) + EIA2 (Innotest) 
 
9 TR ≥ 0.9 tested 1x (for the 2 tests) 31 50 31 25 58.3 550 853 1375 2778 
10 TR1 ≥3 for EIA1 1x and  EIA2 1x: select 
results with TR2≥3 







   




The weakness in our study is that PCR could not be 
tested on the entire series because of the high cost of 
this analysis. Therefore, it was not feasible to 
demonstrate the possible false negatives from screening 
EIA tests. That explains also why the negative predictive 
values (NPVs) were not calculated for indirect diagnosis 
of HCV viremia. 
As for the confirmatory test, Bouare and co-workers 
estimated the PPV PCR+ from LIA that is not equal to 
100% but 81.2% and 82.4% considering the threshold 
TRmax 50% (probably ± 20% of patients recover 
spontaneously according to the literature) (Makuria, 
2012; Ciotti, 2013). Our results confirm the data showing 
that the confirmatory test is not necessary for the 
diagnosis of HCV (Ren, 2005; Pirillo, 2007; Vermeersch, 
2008). Our study data also support the assumption for 
impertinence to repeat the test for positive samples since 
the current tests perform better (Ren, 2005; Pirillo, 2007). 
In addition, the choice of virus identification method 
should be left to the discretion of clinician depending on 
the eligibility criteria. Indeed, all viremic patients do not 
meet the criteria for treatment initiation (Delwaide, 2005). 
While genotyping may no longer be required in the pan-
genotypic antiviral therapy context (Fourati, 2018), non-
response to IFN-free regimens (5%) may be due to 
resistance associated substitutions (RASs) specific for 
each genotype/subtype (Marascio, 2019). However, 
Real-world data are needed to demonstrate the potential 
role of RASs and polymorphisms (Marascio, 2019). Still, 
a more specific HCV test (anti-HCV IgM) (Gerard, 1996) 
can be used in the second or third instance instead of the 
PCR. Similarly, HCVcAg testing in serum is an excellent 
alternative to HCV polymerase chain reaction in Africa 
(Mohamed, 2017). Despite the excellent performance of 
cAg quantification, its implementation on a large scale in 
resource-limited countries presents some limitations, it 
requires a fully equipped laboratory and a trained staff; 
yet these conditions are often limited to big cities in 
resource limited countries (Duchesne, 2017). However, 
EIA-3 test is reported sensitive compared to AxSYM HCV 
Acon® and PCR (Benouda, 2009). The Mixed Ag/Ab EIA 
test with good sensitivity and specificity could be a useful 
alternative tool in settings where direct diagnostic assay 
like PCR are not feasible (Yang, 2011). It could be 
proposed for use, especially in patients with uremia or 
those with HIV infection in whom an early diagnosis 
allows better management. Viremia sensitivity and 
specificity remain the same regardless of the proportion 
of anti-HCV seropositive persons in the cohort being 








point of care testing (in venipuncture blood) followed by 
reflexive quantitative or drawn separated blood nucleic 
acid testing (NAT) are economically comparable and 
viremia sensitive (Chapko, 2015). However, these 
sensitive tests require nucleic acid testing to confirm HCV 
infectious status. As far as HCV serology is concerned, 
false negative results may occur in some contexts such 
as severe immunodeficiency (HIV infection, hypo- or 
agammaglobulinemia), solid organ transplant recipients, 
and patients undergoing hemodialysis (Kalantar-Zadeh, 
2005; Ciotti, 2013). However, cross-reactive circulating 
antigens and antibodies may cause false positive results 
in some conditions such as pregnant women and 
nephritic syndrome autoimmune diseases (Kalem, 2016). 
False positive results of antibody screening tests for HCV 
may lead to unnecessary use of expensive confirmatory 
tests like HCV RNA or RIBA (Kalem, 2016). Our results 
confirm and complement the data previously reported 
(Ren, 2005; Pirillo, 2007). We propose an algorithm that 
confirms the active infection that can be used for HCV 
therapeutic management (discriminates patients more 
likely to be treated). In addition, since the combined 
detection (antigens and antibodies) of HCV may improve 
the sensitivity in contrast to antibody testing alone 
(Laperche, 2005; Nastouli, 2009; El-Emshaty, 2011), our 
method may be proposed for screening blood donors, 
and hemodialysis patients in countries with scarce 
resources provided one uses the test mix as first-line. 
Whether PCR and genotyping present a particular 
interest for both treatment and monitoring (Ciotti, 2013), 
our algorithm is of great interest for HCV diagnosis and 
screening of patients more likely to be treated in Mali. 
This argument is supported by other researchers who 
stated in light of the advances in HCV antiviral therapy, 
global control of HCV infection becomes feasible but 
depends on countries ability to identify infected people 
and treat them (Fourati, 2018). Today, despite the 
progress in HCV screening and diagnosis, it is still 
expensive, and efforts must be made to allow the 
generalized implementation of reliable tests in low and 
middle-income countries (Fourati, 2018). For the 
widespread application of these reliable tests, our 
algorithm may be useful in HCV management in the West 
African area and other low-income countries, before 





The highest PPV was obtained by performing two EIA (4
th
 
generation, ELISA principle) tests and exploitation of the 
threshold (half of the maximal ratio value measured for 
the test, 50% TRmax). The cost of additional tests for 
reliable detection of the virus varied between 3548 USD 
and 1155 USD and the algorithm with the highest PPV 
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